JP2023513738A5 - - Google Patents

Info

Publication number
JP2023513738A5
JP2023513738A5 JP2022548876A JP2022548876A JP2023513738A5 JP 2023513738 A5 JP2023513738 A5 JP 2023513738A5 JP 2022548876 A JP2022548876 A JP 2022548876A JP 2022548876 A JP2022548876 A JP 2022548876A JP 2023513738 A5 JP2023513738 A5 JP 2023513738A5
Authority
JP
Japan
Prior art keywords
compounds
compound
contacting
produced
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548876A
Other languages
English (en)
Japanese (ja)
Other versions
JP7693691B2 (ja
JP2023513738A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000130 external-priority patent/WO2021161109A1/en
Publication of JP2023513738A publication Critical patent/JP2023513738A/ja
Publication of JP2023513738A5 publication Critical patent/JP2023513738A5/ja
Application granted granted Critical
Publication of JP7693691B2 publication Critical patent/JP7693691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548876A 2020-02-14 2021-02-12 P2x3アンタゴニストの製造 Active JP7693691B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062977004P 2020-02-14 2020-02-14
US62/977,004 2020-02-14
US202163144902P 2021-02-02 2021-02-02
US63/144,902 2021-02-02
PCT/IB2021/000130 WO2021161109A1 (en) 2020-02-14 2021-02-12 Preparation of a p2x3 antagonist

Publications (3)

Publication Number Publication Date
JP2023513738A JP2023513738A (ja) 2023-04-03
JP2023513738A5 true JP2023513738A5 (https=) 2024-02-20
JP7693691B2 JP7693691B2 (ja) 2025-06-17

Family

ID=77292130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548876A Active JP7693691B2 (ja) 2020-02-14 2021-02-12 P2x3アンタゴニストの製造

Country Status (11)

Country Link
US (1) US12503470B2 (https=)
EP (1) EP4103572A4 (https=)
JP (1) JP7693691B2 (https=)
KR (1) KR20220140804A (https=)
CN (1) CN115427419B (https=)
AU (1) AU2021219992A1 (https=)
BR (1) BR112022015818A2 (https=)
CA (1) CA3184277A1 (https=)
IL (1) IL295394A (https=)
MX (1) MX2022009765A (https=)
WO (1) WO2021161109A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー3)、リミテッド P2x3修飾薬での治療
WO2022156783A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
CN114805237B (zh) * 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
EP4577528A1 (en) * 2022-08-25 2025-07-02 14245563 Canada Inc. Preparation of a p2x3 antagonist
WO2025125445A1 (en) 2023-12-12 2025-06-19 Glaxosmithkline Intellectual Property (No.3) Limited Process of manufacture of p2x3 antagonists including camlipixant
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2026022326A1 (en) 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010229142A1 (en) * 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
CN102358739B (zh) * 2011-04-29 2013-02-20 中国科学院广州生物医药与健康研究院 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法
DK3381917T3 (da) * 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
KR102797127B1 (ko) * 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
EP4103564A4 (en) * 2020-02-14 2024-05-01 GlaxoSmithKline Intellectual Property (No.3) Limited P2X3 MODULATORS
WO2021244634A1 (zh) 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
EP4169921A4 (en) 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
WO2022156783A1 (zh) 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
CN114805237B (zh) 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体

Similar Documents

Publication Publication Date Title
JP2023513738A5 (https=)
JP2007515465A5 (https=)
JP2010510221A5 (https=)
JP2010522227A5 (https=)
JP2014208676A5 (https=)
JP2006506425A5 (https=)
JP2021073241A (ja) 癌を処置する方法
JP2015044834A5 (https=)
JP2011528658A5 (https=)
JP2012211164A5 (https=)
JP2008094834A5 (https=)
TW201202253A (en) Process for preparing carbamoylpyridone derivatives and intermediates
MXPA01004432A (es) Nuevos esteres derivados de compuestos fenilciclohexil sustituidos.
JP2008501776A5 (https=)
JP2011103887A5 (https=)
JP2007533722A5 (https=)
JP2009532434A5 (https=)
JP2009541209A5 (https=)
JP2007302689A5 (https=)
JP2018531247A5 (https=)
JP2009519350A5 (https=)
JP2019151627A5 (https=)
JP2007515467A5 (https=)
JP2008546809A5 (https=)
TWI505826B (zh) 乙醯胺立體異構物